ALLO Aug 2023 12.500 call
| Previous Close | 0.1000 |
| Open | 0.1000 |
| Bid | 0.0500 |
| Ask | 0.0000 |
| Strike | 12.50 |
| Expire Date | 2023-08-18 |
| Day's Range | 0.1000 - 0.1000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 25 |
GlobeNewswireAllogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting
Long Term Follow Up Data from Phase 1 ALPHA/ALPHA2 Trials Demonstrate Potential of Allogeneic CD19 CAR T to Generate Durable Complete Responses Similar to Approved Autologous Therapies Presentation Focused on Patients (n=12) Treated with Phase 2 Regimen67% Overall Response Rate (ORR) and 58% Complete Response (CR) RateFive Patients (42%) Maintained a CR at Month 6; Four of Five CRs (80%) Ongoing Beyond Six Months, Including Two at 30+ Months and One at 24+ Months Clinical Safety and Immune Recov
ZacksAllogene Therapeutics (ALLO) Down 17.5% Since Last Earnings Report: Can It Rebound?
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ZacksSanofi (SNY) NextGen Multiple Sclerosis Drug Meets Phase II Goal
Sanofi's (SNY) phase II study on its novel investigational anti-CD40L antibody, frexalimab, meets the primary endpoint.
ZacksJ&J (JNJ) Submits NDA for Single Tablet Combo to Treat PAH
J&J (JNJ) submits a new drug application for a single tablet combination therapy of macitentan and tadalafil for the long-term treatment of pulmonary arterial hypertension.
ZacksAstraZeneca (AZN) Drug Combo Meets Endometrial Cancer Study Goal
AstraZeneca (AZN) reports statistically significant results from a late-stage study evaluating the combination of Imfinzi and Lynparza in patients with advanced endometrial cancer.
ZacksApellis' (APLS) Study on Pegcetacoplan to Treat ALS Fails
Apellis' (APLS) phase II MERIDIAN study on pegcetacoplan for the treatment of amyotrophic lateral sclerosis fails to meet primary and key secondary endpoints.
ZacksWall Street Analysts See a 210.24% Upside in Allogene Therapeutics (ALLO): Can the Stock Really Move This High?
The mean of analysts' price targets for Allogene Therapeutics (ALLO) points to a 210.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
ZacksPDS Biotech (PDSB) Up 32% on Interim Data From HPV Cancer Study
PDS Biotech's (PDSB) shares gain as it announces encouraging interim data from the VERSATILE-002 study for treating HPV16-positive cancer patients.
ZacksImmutep (IMMP) Up on Initial Data From Lung Cancer Study
Immutep (IMMP) shares surge on encouraging initial data from a triple combination therapy study, INSIGHT-003, for non-small cell lung cancer.
- Zacks
Icosavax (ICVX) Up on Positive VLP Vaccine Candidate Data
Icosavax (ICVX) surges on positive data from the clinical study of IVX-A12, targeting respiratory syncytial virus and human metapneumovirus in older adults.
- GlobeNewswire
Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will participate in three upcoming investor conferences. TD Cowen 4th Annual Oncology Innovation SummitTuesday, May 30, 20236:30AM PT/9:30AM ET Jefferies Healthcare ConferenceFriday, June 9, 20239:45AM PT/12:45PM ET Goldman Sachs 44th Annual Global H
ZacksINOVIA's (INO) Rare Disease Drug Gets EC's Orphan Tag, Stock Up
INOVIA (INO) shares surge 12% in the after-market hours, when its drug for treating a rare respiratory tract disease, INO-3107, receives orphan drug designation from the European Commission.
Simply Wall St.We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
- Zacks
PDS Biotech (PDSB) Completes Enrollment for HPV Cancer Study
PDS Biotech (PDSB) shares gain as it completes patient enrollment in the second arm of the VERSATILE-002 study for treating HPV16-positive cancer patients.
ZacksAbbVie's (ABBV) Rinvoq Gets FDA Nod to Treat Crohn's Disease
AbbVie (ABBV) announces the seventh FDA approval of its JAK inhibitor, Rinvoq, for the treatment of adults with moderately to severely active Crohn's disease.
InvestorPlace7 Short-Interest Stocks to Target for Explosive Gains
Ranking among the most speculative practices in the equities arena, deliberately bidding up short-interest stocks may generate wildly robust gains. At the same time, higher risks for the intrepid market participant also signifies substantial risks. Fundamentally, triggering emotions of panic undergird short-squeeze stocks. When bearish traders “attack” a security, they aim to profit from their value erosion. However, if the underlying security rises in value, they lose. Because no upside ceiling
ZacksMindMed (MNMD) Up on 50% Enrollment in Anxiety Disorder Study
MindMed's (MNMD) mid-stage study, evaluating MM-120 for treating general anxiety disorder, reaches over 50% enrollment mark. Its top-line data is expected in late 2023.
ZacksUltragenyx's (RARE) GTX-102 Gets FDA Nod for Uniform Dosing
Ultragenyx (RARE) stock climbs 5% after the FDA agrees to a protocol amendment to the phase I/II study of GTX-102 in pediatric patients with Angelman syndrome.
ZacksIntercept's (ICPT) Liver Drug Combo Gets FDA's Orphan Drug Tag
Intercept's (ICPT) fixed-dose combination of obeticholic acid and bezafibrate for the potential treatment of primary biliary cholangitis gets the FDA's Orphan Drug Designation.
ZacksPHIO's Skin Cancer Candidate to Enter Clinical Study, Stock Up
PHIO surges on the FDA clearance of investigational new drug application for its lead product, PH-762, for the treatment of skin carcinomas.
ZacksBayer's (BAYRY) Arrhythmia Prevention Drug Gets Fast Track Tag
Bayer's (BAYRY) oral FXIa inhibitor, asundexian, gets the FDA's Fast Track Designation, as a preventive treatment for stroke and systemic embolism in people with atrial fibrillation.
ZacksArcus (RCUS) & Gilead Re-Collaborate for Inflammatory Diseases
Arcus (RCUS) surges as it expands its previous research collaboration with partner Gilead, to focus on developing therapies for inflammatory diseases.
ZacksImmunoGen (IMGN) Stock Surges 230% in a Month: Here's Why
ImmunoGen (IMGN) shares surge exponentially in the past month owing to the positive data on the expansion study of Elahere for ovarian cancer. An encouraging initial sales uptake of its first marketed product, Elahere, also contribute to the surge.
- Zacks
FDA Rejects ImmunityBio's (IBRX) Bladder Cancer Therapy Filing
FDA rejects ImmunityBio's (IBRX) filing seeking approval of Anktiva (N-803) as a combo-therapy in bladder cancer indication, citing deficiencies in an inspection of contract manufacturing firms.
ZacksCorvus Pharma (CRVS) Stock Surges 69.2% in a Week: Here's Why
Shares of Corvus Pharma (CRVS) surge 69% this week after the company provided updates on its pipeline development in the first quarter of 2023 earnings release.
